Literature DB >> 23398681

Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test.

A Tripodi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23398681     DOI： 10.1111/jth.12166

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  7 in total

1.  Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect.

Authors:  Toshiaki Iba; Mari Emmi; Makoto Hiki; Masataka Nagayama; Koichiro Aihara; Yoko Tabe; Maiko Yuri; Akimichi Ohsaka
Journal:  Int J Hematol       Date:  2016-03-16       Impact factor: 2.490

2.  Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.

Authors:  Lisa M Baumann Kreuziger; Mark T Reding
Journal:  Thromb Res       Date:  2013-07-31       Impact factor: 3.944

3.  Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.

Authors:  Bohyun Kim; Seongsoo Jang; Yu-Jin Lee; Nuree Park; Young-Uk Cho; Chan-Jeoung Park
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

4.  Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban.

Authors:  Armando Tripodi; Ida Martinelli; Veena Chantarangkul; Marigrazia Clerici; Andrea Artoni; Serena Passamonti; Flora Peyvandi
Journal:  Int J Hematol       Date:  2015-11-19       Impact factor: 2.490

Review 5.  Coagulation assessment with the new generation of oral anticoagulants.

Authors:  Charles V Pollack
Journal:  Emerg Med J       Date:  2015-05-18       Impact factor: 2.740

6.  Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).

Authors:  Priscilla Bento Matos Derogis; Livia Rentas Sanches; Valdir Fernandes de Aranda; Marjorie Paris Colombini; Cristóvão Luis Pitangueira Mangueira; Marcelo Katz; Adriana Caschera Leme Faulhaber; Claudio Ernesto Albers Mendes; Carlos Eduardo Dos Santos Ferreira; Carolina Nunes França; João Carlos de Campos Guerra
Journal:  PLoS One       Date:  2017-02-07       Impact factor: 3.240

7.  Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs.

Authors:  Raul Altman; Claudio Daniel Gonzalez
Journal:  Thromb J       Date:  2014-03-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.